SCHEMBL2825342

SCHEMBL2825342

COc1ccc(-c2nnc3c4ccccc4c(Nc4cccc(C(=O)N5CCN(C)CC5)c4)nn23)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.51
TP53 P04637 3/20 0.51
LMNA P02545 3/20 0.51
SMN1; SMN2 Q16637 3/20 0.48
NPSR1 Q6W5P4 2/20 0.48
NPC1 O15118 1/20 0.48
RAB9A P51151 1/20 0.48
SMO Q99835 1/20 0.45
ALDH1A1 P00352 1/20 0.44
HPGD P15428 1/20 0.44
GABRA1 P14867 1/20 0.44
GABRG2 P18507 1/20 0.44
GABRB3 P28472 1/20 0.44
GABRA5 P31644 1/20 0.44
GABRA3 P34903 1/20 0.44
GABRA2 P47869 1/20 0.44
POLB P06746 3/20 0.43
SRC P12931 1/20 0.43
BRD4 O60885 1/20 0.43
CREBBP Q92793 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2825195 0.91 RAB9A (0.53) MAPTTP53LMNASMN1; SMN2NPSR1
SCHEMBL2826701 0.91 MAPT (0.50) MAPTTP53LMNASMN1; SMN2NPSR1
SCHEMBL2825575 0.87 MAPT (0.57) MAPTTP53LMNASMN1; SMN2NPSR1
SCHEMBL2826541 0.86 MAPT (0.54) MAPTTP53LMNASMN1; SMN2NPSR1
SCHEMBL2831941 0.85 MAPT (0.53) MAPTTP53LMNASMN1; SMN2NPSR1
SCHEMBL2828318 0.85 MAPT (0.53) MAPTTP53LMNASMN1; SMN2NPSR1
SCHEMBL2832052 0.85 MAPT (0.56) MAPTTP53LMNASMN1; SMN2NPSR1
SCHEMBL2825452 0.85 MAPT (0.54) MAPTTP53LMNASMN1; SMN2NPSR1
SCHEMBL2825279 0.84 MAPT (0.52) MAPTTP53LMNASMN1; SMN2NPSR1
SCHEMBL2831680 0.83 MAPT (0.55) MAPTTP53LMNASMN1; SMN2NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1791543-B1 TRIAZOLOPHTHALAZINES NYCOMED GMBH (DE) 2010-06-16 EP claimed
US-7851472-B2 Triazolophthalazines NYCOMED GMBH (DE) 2010-12-14 US disclosed
US-20100286140-A1 TRIAZOLOPHTHALAZINES NYCOMED GMBH (DE) 2010-11-11 US disclosed
EP-1791543-B1 TRIAZOLOPHTHALAZINES NYCOMED GMBH (DE) 2010-06-16 EP disclosed
US-20090005372-A1 Triazolophthalazines ALTANA PHARMA AG (DE) 2009-01-01 US disclosed
EP-1791543-A2 TRIAZOLOPHTHALAZINES Altana Pharma AG (DE) 2007-06-06 EP disclosed
WO-2006024640-A2 TRIAZOLOPHTHALAZINES ALTANA PHARMA AG (DE) 2006-03-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100286140-A1 TRIAZOLOPHTHALAZINES PDE2A, PDE12, PDE3A MAPT 3816/4885TP53 4660/4885LMNA 3740/4885
US-20090005372-A1 Triazolophthalazines PDE2A, PDE12, PDE3A MAPT 3816/4885TP53 4660/4885LMNA 3740/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.